RxDoctor Payments Data

David Rand, MD

Ophthalmology · Pompano Beach, FLNPI 1548491491

Payments from drug & device makers

$68,025in general payments, 2019–2025

Across 28 payments — averaging $2429.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$67K
  • Mallinckrodt Hospital Products Inc.$386
  • Genentech, Inc.$61
  • Johnson & Johnson Surgical Vision, Inc.$58
  • Eyevance Pharmaceuticals LLC$34
  • AbbVie$29
  • plus $110 from 6 others

What the payments were for

  • Food & beverage$41159%
  • Education$28441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$68,025 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$466,488
Medicare patients
1,279
Services billed
5,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost50$22,013
LumiganBimatoprost53$21,120
CombiganBrimonidine Tartrate/Timolol53$17,022
RestasisCyclosporine26$15,955
VyzultaLatanoprostene Bunod19$13,914
Prednisolone Acetate437$13,676
Cyclosporine17$8,146
Alphagan PBrimonidine Tartrate13$6,662
Latanoprost792$5,865
Ketorolac Tromethamine271$5,729
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$4,659
XiidraLifitegrast11$4,407
Brimonidine Tartrate407$4,404
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat259$3,594
Ofloxacin325$3,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$29$60,759145 claims
Aerie Pharmaceuticals, Inc.Rocklatan$22$22,01350 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$24$18,32130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Pompano Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →